Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.37 |
| ▸ | MVD | P53602 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258054 | 0.84 | PLA2G2A (0.43) | BTN3A1ALDH1A1PLA2G2A | |
| SCHEMBL15259067 | 0.83 | ALDH1A1 (0.43) | BTN3A1ALDH1A1PLA2G2AMVDLMNA | |
| SCHEMBL11595897 | 0.81 | TSHR (0.48) | BTN3A1ALDH1A1PLA2G2ALMNAMGAM | |
| SCHEMBL11908881 | 0.80 | ALDH1A1 (0.39) | BTN3A1ALDH1A1LMNASLC15A2MGAM | |
| SCHEMBL1198793 | 0.79 | LPAR3 (0.46) | BTN3A1ALDH1A1LMNASLC15A2 | |
| SCHEMBL15257420 | 0.78 | BTN3A1 (0.42) | BTN3A1ALDH1A1MVD | |
| SCHEMBL17482402 | 0.77 | PLA2G2A (0.39) | BTN3A1PLA2G2AMVDMGAMGAA | |
| SCHEMBL19699811 | 0.77 | LPAR3 (0.43) | BTN3A1PLA2G2A | |
| SCHEMBL6352756 | 0.77 | BTN3A1 (0.38) | BTN3A1ALDH1A1PLA2G2AMVD | |
| SCHEMBL19605920 | 0.76 | BTN3A1 (0.41) | BTN3A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265121-A9 | CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE | DUKE UNIVERSITY | 2023-08-24 | — | — | US | disclosed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | BTN3A1 1242/4885ALDH1A1 2511/4885PLA2G2A 3834/4885 |
| US-20230265121-A9 | CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE | SHBG, TACR2, GAP43 | BTN3A1 622/4885ALDH1A1 610/4885PLA2G2A 468/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | BTN3A1 3226/4885ALDH1A1 1204/4885PLA2G2A 415/4885 |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | CYP51A1, HSD11B1, HSD3B1 | BTN3A1 601/4885ALDH1A1 1545/4885PLA2G2A 2515/4885 |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | BTN3A1 3226/4885ALDH1A1 1204/4885PLA2G2A 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.